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A reduction of the nitric oxide (NO) action in vascular smooth muscle cells (VSMC) could play a role in the vascular damage
induced by the glycaemic excursions occurring in diabetic patients; in this study, we aimed to clarify whether a short-term
incubation of cultured VSMC with high glucose reduces the NO ability to increase cGMP and the cGMP ability to phosphorylate
VASP at Ser-239. We observed that a 180min incubation of rat VSMC with 25mmol/L glucose does not impair the NO-induced
cGMP increase but reduces VASP phosphorylation in response to both NO and cGMP with a mechanism blunted by antioxidants.
We further demonstrated that high glucose increases radical oxygen species (ROS) production and that this phenomenon is
prevented by the PKC inhibitor chelerythrine and the NADPH oxidase inhibitor apocynin. The following sequence of events is
supported by these results: (i) in VSMC high glucose activates PKC; (ii) PKC activates NADPH oxidase; (iii) NADPH oxidase
induces oxidative stress; (iv) ROS impair the signalling of cGMP, which is involved in the antiatherogenic actions of NO.Thus, high
glucose, via oxidative stress, can reduce the cardiovascular protection conferred by the NO/cGMP pathway via phosphorylation of
the cytoskeleton protein VASP in VSMC.
1. Introduction
Among the factors involved in the huge increase of cardio-
vascular risk occurring in diabetes mellitus, a pivotal role is
played by a reduced synthesis and action of nitric oxide (NO)
[1], a substance exerting a major role in vascular biology by a
wide array of antihypertensive and antiatherogenic properties
[2–4]. As it is widely recognized, in diabetes mellitus there
is a reduced synthesis of NO by vascular endothelium, mir-
rored by a reduction of the so-called “endothelial-dependent
relaxation,” that is, the “in vivo” vasodilation induced by
agents able to stimulate the endothelial synthesis of NO [5,
6]. More controversial is the impairment of the NO action
in diabetic patients: for instance, in some studies the so-
called “endothelium-independent” relaxation (i.e. the vasodi-
lation induced by exogenous administration of NO donors)
is preserved in the presence of an impaired “endothelial-
dependent relaxation” [7–9], whereas in other studies both
the endothelial and the non-endothelial-dependent relax-
ation are impaired [10–14].
Therefore, since the endothelial-independent vasodila-
tion mirrors the response of vascular smooth muscle cells
(VSMCs) to NO, it has not been completely clarified as yet
whether in the presence of diabetes mellitus these cells show
a normal or an impaired response to NO, at least as far as
vasodilation is concerned.
One of the main actions of NO is to activate the soluble
guanylate cyclase (sGC), with the consequent biosynthesis of
cyclic guanosine 3󸀠,5󸀠-monophosphate (cGMP), an ubiqui-
tous intracellular second messenger which mediates a large
spectrum of biological processes, such as cell contractility,
mobility, growth, and apoptosis: the relevance of cGMP
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signalling in cardiovascular pathophysiology and therapeu-
tics has been exhaustively reviewed [4, 15]. In particular,
cGMP deeply influences VSMC contractility, proliferation,
and switch from the contractile “differentiated” to the syn-
thetic/secretory “de-differentiated” phenotype [16].The influ-
ence of cGMP on the cardiovascular system is exerted by acti-
vating cGMP-dependent protein kinases and phosphatases
[15, 17].
The main cGMP-dependent protein kinase in VSMC
is PKG type I [15]: the sequential activation of sGC and
PKG plays a crucial role in NO action. In particular,
downregulation of both enzymes impairs the NO ability to
modulate VSMC functions, leading to excessive proliferation,
constriction, and secretory activity, as observed in vascular
disorders, and ablation of the PKGgene deeply interferes with
NO/cGMP-dependent VSMC relaxation both “in vivo” and
“in vitro” [18].
One of the PKG-I actions is the phosphorylation, mainly
at serine 239, of the vasodilatory-stimulated phosphoprotein
(VASP): VASP is a thin filament-actin binding cytoskeletal
protein playing a pivotal role in cell adhesion, motility, and
migration and—by binding to actin filaments and stress
fibers—in cell contraction [19–23]. Thus, VASP phosphory-
lation at serine 239 is not only a marker of PKG activation
but also a mediator of relevant biological actions exerted by
the NO/cGMP/PKG pathway, such as modulation of actin
polymerization, cell-cell contacts, and relaxation [19–23].
Dysfunction of the cGMP signalling at any level occurs in
many cardiovascular diseases, such as arterial and pulmonary
hypertension, atherosclerosis, cardiac hypertrophy, vascular
remodelling, myocardial ischemia, and heart failure [15].The
dysfunction of the cGMP signalling in diabetesmellitus needs
to be further elucidated, as previously mentioned.
Since hyperglycaemia is the main biochemical feature of
diabetes mellitus, we aimed to clarify in this study whether
high glucose impairs in VSMC the ability of NO to increase
the synthesis of cGMP and to activate the downstream
cascade of events leading to VASP phosphorylation; fur-
thermore, we aimed to clarify the mechanisms involved in
this putative impairment, with a peculiar emphasis for the
oxidative stress, which is deeply involved in the pathogenesis
of diabetes vascular complications and mediates the vascular
damage induced by hyperglycaemia [24, 25].
In particular, we aimed at investigating the role of a short-
term VSMC incubation with high glucose: the rationale of
our experimental design “in vitro” is the fact that in the last
years it has been observed that acute increases of blood glu-
cose concentrations “in vivo,” the so-called “glucose spikes,”
mainly occurring after meals, confer a high cardiovascular
risk attributed to acute increases of oxidative stress [26].
Interestingly, in a prospective study carried out in our
diabetes clinic, we demonstrated that postprandial blood
glucose is a stronger predictor of cardiovascular events and
death than fasting blood glucose even after the correction
for the long-term glucose control marker haemoglobin A1C
[27, 28].
In the light of these clinical observations, we decided
to evaluate the influence of short-term incubations with
high glucose on the NO/cGMP pathway in VSMC and the
potential role of oxidative stress.
We also aimed at evaluating the role of protein kinase
C (PKC) in the putative glucose-induced, oxidative stress-
mediated impairment of the NO-cGMP signalling in VSMC,
since one of the main mechanisms linking high glucose
and oxidative stress is the glucose-induced activation of
PKC, which in turn activates the superoxide anion gener-
ating enzyme nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase [29].
2. Materials and Methods
2.1. Research Design. The study has been carried out in
cultured rat aortic VSMC.
(a) To evaluate whether high glucose reduces the NO
ability to increase the VASP phosphorylation at serine
239, aortic VSMCs were incubated for 60min with
the NO donor SNP (100 𝜇mol/L) with or without
a 120min preincubation of 25mmol/L glucose to
measure VASP phosphorylation at serine 239: in the
following part of the paper, we will indicate this kind
of phosphorylation simply as “VASP phosphoryla-
tion.”
(b) To evaluate whether the glucose-induced impair-
ment of the NO ability to phosphorylate VASP is
attributable to a reduction of the NO ability to
increase cGMP, cGMP concentrations have been
measured in aortic VSMC incubated for 60min with
the NO donor SNP (100𝜇mol/L) with or without a
120min preincubation with 25mmol/L glucose.
(c) To evaluate whether high glucose reduces the cGMP
ability to phosphorylateVASP,VASPphosphorylation
has been measured in aortic VSMC incubated for
60min with the cell-permeable cGMP analog 8-
Br-cGMP (500𝜇mol/L) with or without a 120min
preincubation with 25mmol/L glucose.
(d) To evaluate the involvement of oxidative stress on
the high glucose-induced impairment of the NO- and
cGMP-induced VASP phosphorylation, the experi-
ments described at points (a) and (c) were repeated
in the presence of a 20min preincubation with the
ROS scavenging enzymes SOD (300U/mL) + catalase
(250U/mL).
(e) To evaluate whether high glucose increases radical
oxygen species (ROS) production in VSMC and
whether this increase is attributable to a PKC-induced
activation of NADPH oxidase, ROS concentrations
were measured in VSMC with or without a 180min
incubation with 25mmol/L glucose, in the absence
or in the presence of a 20min preincubation with
the PKC inhibitor chelerythrine (2.5 𝜇mol/L) and the
NADPH oxidase inhibitor apocynin (10 𝜇mol/L). To
evaluate the putative influence on ROS production
of two other ROS sources, that is, the mitochon-
drial electron transport chain complex and xanthine
oxidase, experiments with 25mmol/L glucose were
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also repeated in the presence of a 20min preincuba-
tion with their specific inhibitors, that is, rotenone
(10 𝜇mol/L) and allopurinol (50 𝜇mol/L), respec-
tively. Finally, as a control experiment for themethods
employed, experiments with 25mmol/L glucose were
repeated in the presence of a 20min preincubation
with 300U/mL SOD + 250U/mL catalase when
hydrogen peroxidewasmeasured and 300U/mLSOD
when superoxide anion was measured.
(f) To evaluate whether high glucose increases PKC
alpha-beta phosphorylation, the phosphorylation of
PKC 𝛼/𝛽II was measured in VSMC with or without a
180min incubation with 25mmol/L glucose.
(g) To evaluate whether activation of PKC and NADPH
oxidase mediates the influence of high glucose on
the VASP phosphorylation in response to cGMP,
experiments described at point (c) were repeated
in the presence of a 20min preincubation with
2.5 𝜇mol/L chelerythrine and 10 𝜇mol/L apocynin.
Experiments have been also repeated in the presence
of 10 𝜇mol/L rotenone, to exclude the influence of the
mitochondrial electron transport chain complex.
2.2. Chemicals. Minimum essential medium (MEM), bovine
serum albumin (BSA), sodium nitroprusside (SNP), 8-Br-
cGMP, lucigenin, CaCl
2
, MgCl
2
, 4𝛽-phorbol 12-myristate
13-acetate (PMA), superoxide dismutase (SOD), catalase,
chelerythrine, apocynin, rotenone, and allopurinolwere from
Sigma-Aldrich (St. Louis, MO, USA). Dihydrodichloroflu-
orescin diacetate was from Invitrogen Molecular Probes
(Paisley, UK). Compounds used for western blots are detailed
in the specific paragraphs.
2.3. Animals and VSMC Culture. Experiments have been
carried out in VSMC derived from aorta of lean Zucker rats
isolated and cultured in our laboratory. In particular, male
and age-matched rats (𝑛 = 4), purchased from Charles
River Laboratories (Calco, Italy), were fed with standard
rodent chow and water ad libitumuntil 14 weeks old and
killed with CO
2
after 12-hour fasting. Aorta was processed
for VSMC isolation, culture, and characterization. Cells were
characterized by phenotype and checked for the presence
of smooth muscle cell 𝛼-actin and the absence of factor
VIII (staining with a fluorescein isothiocyanate-conjugated
antibody specific for factor VIII antigen). Cells were cultured
using MEM (containing 5mmol/L glucose) supplemented
with 10% fetal calf serum (FCS), 10mM glutamine, and
antibiotics, and bufferedwith 10mMN-Tris (hydroxymethyl)
methyl-2-aminoethane-sulphonic acid (TES) and 10mM
N-(2-hydroxyethyl) piperazine-N1-(2-ethanesulphonic acid)
(HEPES). For the experiments, cells were used at 3th-4th
passage and cultured until 70% confluence was achieved.
Then, medium with serum was removed and cells were
made quiescent by serum starvation and cultured in MEM
containing 0.1% BSA. Experiments have been carried out
following the National Institutes of Health Guide for the Care
and Use of Laboratory Animals 1996 (7th ed.; Washington,
DC: National Academy Press, National Research Council
Guide) and approved by our Institution.
2.4. Intracellular cGMP Measurement. For intracellular
cGMP measurementcells were cultured into 6-well plates
with medium containing 10% FCS until 70% confluence
was achieved; the medium was then removed and replaced
overnight with medium containing 0.1% BSA. At the end of
the different incubation periods, medium was removed from
each well and 300 𝜇L absolute ethanol was added. A complete
evaporation of ethanol was obtained under shaking. Then,
the precipitated was dissolved in 300 𝜇L acetate buffer and
kept at −70∘C until the assays. cGMP was measured by RIA
kits (Immuno Biological Laboratories, Hamburg, Germany).
The sensitivity of assay was less than 0.3 fmol per 0.1mL,
the specificity was 100% for cGMP, 0.0004% for cAMP, and
0.0001% for guanosine monophosphate (GMP), guanosine
diphosphate (GDP), adenosine triphosphate (ATP), and
guanosine triphosphate (GTP), and intra-assay coefficient
of variation was 4.4%. Results were expressed as picomoles
cGMP per milligram cell proteins.
2.5. Protein Expression and Extent of Protein Phosphorylation
by Western Blot. To evaluate the protein expression and the
extent of protein phosphorylation by western blot, VSMC
extracts (20 𝜇g) were separated by 10% SDS-PAGE and
transferred to Immobilon-P Transfer Membranes (Millipore
Co, Bedford, MA, USA). Membranes were incubated with
the following primary antibodies: rabbit polyclonal anti-
total VASP (1 : 15000) and mouse monoclonal anti-VASP
phosphorylation at Ser 239 (1 : 1000) (Santa Cruz Biotec-
nology Inc., CA, USA); rabbit polyclonal anti-PKC (𝛼/𝛽/𝛾)
(1 : 1000) (Upstate, USA) and rabbit polyclonal phospho-
PKC 𝛼/𝛽II (Thr 638/641) (1 : 1000) (Cell Signalling, USA).
We used as secondary antibodies anti-rabbit (1 : 10000) or
anti-mouse (1 : 50000) conjugated to horseradish peroxidase.
All the antibodies were diluted in PBS containing 0.1%
Tween-20 (Sigma-Aldrich). Blots were scanned and analyzed
densitometrically by the image analyzer 1D Image Analysis
software (Kodak, Rochester, NY).
2.6. Determination of Cellular Reactive Oxygen Species (ROS).
ROS were measured by using the DCF-DA assay, more
specific for detection of hydrogen peroxide, and the lucigenin
assay, more specific for the detection of superoxide anion.
2.6.1. The DCF-DA Assay. This assay was carried out by
using the sensitive fluorescent indicator 2󸀠,7󸀠-dihydrodi-
chlorofluorescin diacetate (DCF-DA), a diacetylated fluores-
cence probe which diffuses into the cells, where intracellular
esterases cleave the acetyl groups, and is oxidized by H
2
O
2
to the highly fluorescent 2󸀠,7󸀠-dichlorodihydrofluorescein
(DCF) [30].
In particular, VSMCs cultured in 96-multiwell plates
(1 × 105mL−1) were incubated with MEM with BSA 0.1%
containing 5 or 25mmol/L glucose for 3 h at 37∘C. Posi-
tive control cells were incubated with 5mmol/L glucose in
the presence of 4𝛽-phorbol 12-myristate 13-acetate (PMA)
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(10 𝜇mol/L) for 1 h, washed, and loaded with DCF-DA. After
treatment, the medium was aspirated and cells were washed
with PBS containing 1mM CaCl
2
and 1mM MgCl
2
(PBS+)
and incubated in the dark for 60min at 37∘C in the presence
of 10 𝜇Mof DCF-DA. After that, cells were washed with PBS+
and the emitted DCF fluorescence was collected and mea-
sured using a plate fluorometer (GloMax-Multi Detection
System, Promega Corporation, Madison, WI, USA) fitted
with 490 nm excitation and 520 nm emission filters. Each
assay was carried out with six replicates and the fluorescence
measure for each treatment was the average value of at least
three independent experiments. ROS intracellular levels were
expressed as fold increase fromvalueswith 5mmol/L glucose.
2.6.2. The Lucigenin Assay. O
2
− levels were measured by
lucigenin-enhanced chemiluminescence method based on
light emission from reaction between reduced lucigenin and
O
2
− as previously described [31]. Briefly, VSMCs, after a
24 h serum starvation, were resuspended at 5 × 105 cells/mL
into a luminometer cuvette containing phosphate buffer and
maintained at 37∘C for 10min. After a 5 sec dark adaptation,
lucigenin (final concentration 25𝜇mol/L) was added into
the cuvette and chemiluminescence was recorded 3 sec after
the last injection over a 60min period at 1min intervals by
the luminescence reader (GloMax-Multi Detection System,
Promega Corporation, Madison, WI, USA). Specificity of
reaction for O
2
− was demonstrated by preincubating cells
with extracellular SOD (300U/mL). Chemiluminescence
activity unit is the relative light unit and O
2
− intracellular
levels were expressed as relative light unit per cell.
2.7. Statistical Analysis. Data are expressed as means ±
standard error of the mean (S.E.M). Statistical analysis was
performed by means of analysis of variance (ANOVA) to
determine the statistical significance of dose-response effects
and by unpaired Student’s t-test when only two values were
compared.
3. Results
3.1. High Glucose Reduces the SNP-Induced VASP Phospho-
rylation at Ser 239. As shown in Figure 1, (i) high glucose
did not modify VASP expression and phosphorylation in
the absence of SNP; (ii) SNP did not modify total VASP
expression neither in the absence nor in the presence of high
glucose; (iii) SNP induced a significant VASP phosphoryla-
tion in the presence of both 5mmol/L (𝑛 = 6, 𝑃 < 0.0001)
and 25mmol/L glucose (𝑛 = 6, 𝑃 = 0.003), the percent values
on baseline being 602.4 ± 17% and 165.7 ± 10.9%, respectively.
In the presence of 25mmol/L glucose, values were significant
lower than in the presence of 5mmol/L glucose (𝑃 < 0.0001).
3.2. High Glucose Does Not Modify the SNP-Induced Increase
of cGMP. As shown in Figure 2, SNP induced a significant
increase of cGMP concentrations in the presence of both
5mmol/L glucose (𝑛 = 6,𝑃 < 0.0001) and 25mmol/L glucose
(𝑛 = 6, 𝑃 < 0.0001), without significant differences between
the two glucose concentrations.
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Figure 1: Effects of a 120min preincubation with 5 and 25mmol/L
glucose on total VASP expression and VASP phosphorylation at
Ser 239 in the absence or in the presence of a 60min incubation
with the NO donor SNP (100𝜇mol/L). Blots are representative of
six different experiments. The increase induced by SNP on VASP
phosphorylation at both 5 and 25mmol/L (𝑃 < 0.0001 and 𝑃 =
0.003, respectively) was lower at 25 than at 5mmol/L (𝑃 < 0.0001).
SNP did not modify total VASP expression neither in the absence
nor in the presence of high glucose.
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Figure 2: Effects of a 120min preincubation with 5 and 25mmol/L
glucose on cGMP production in the absence or in the presence of
a 60min incubation with the NO donor SNP (100𝜇mol/L). The
increase induced by SNP at both 5 and 25mmol/L (𝑛 = 6,𝑃 < 0.0001
for both) was similar for both glucose concentrations (𝑃 = ns).
3.3. High Glucose Reduces the cGMP-Induced VASP Phos-
phorylation at Ser 239. As shown in Figure 3, 8-Br-cGMP
induced a significant VASP phosphorylation in the presence
of 5mmol/L (𝑛 = 6, 𝑃 < 0.0001), 15mmol/L (𝑛 = 6, 𝑃 <
0.0001), and 25mmol/L glucose (𝑛 = 6, 𝑃 < 0.0001). When
values are expressed as percent of baseline values at glucose
5mmol/L, the extent of VASP phosphorylation induced by
8-Br-cGMP dose dependently decreased (ANOVA: 𝑃 <
0.0001).
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Figure 3: Effects of a 120min preincubation with 5, 15, and
25mmol/L glucose on VASP phosphorylation at Ser 239 in the
absence or in the presence of a 60min incubation with the cell-
permeable cGMP analog 8-Br-cGMP (500 𝜇mol/L). Blots are rep-
resentative of six different experiments. 8-Br-cGMP induced a sig-
nificant VASP phosphorylation at the three glucose concentrations
(𝑃 < 0.0001 for each of them).When values are expressed as percent
of values at glucose 5mmol/L, the extent of VASP phosphorylation
induced by 8-Br-cGMP dose dependently decreased (ANOVA: 𝑃 <
0.0001).
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Figure 4: Effects of a 20min preincubation with the antioxidant
mixture SOD (300U/mL) + catalase (250U/mL) on the SNP-
induced VASP phosphorylation at Ser 239 in the presence of 5
and 25mmol/L glucose. Blots are representative of six different
experiments. SOD and catalase did not modify the significant
increase of VASP phosphorylation induced by SNP in the presence
of 5mmol/L glucose but significantly increased the extent of the
SNP-induced VASP phosphorylation in the presence of glucose
25mmol/L (𝑃 < 0.0001).
3.4. The Antioxidant Mixture SOD + Catalase Prevents the
Inhibitory Effects Exerted by High Glucose on the VASP Phos-
phorylation Induced by SNP and by 8-Br-cGMP. As shown in
Figures 4 and 5, the antioxidant mixture SOD + catalase did
not modify the extent of VASP phosphorylation induced by
SNP or 8-Br-cGMP in the presence of 5mmol/L glucose but
restored the inhibitory effects induced by 25mmol/L glucose
(𝑛 = 6, 𝑃 < 0.0001 for both).
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Figure 5: Effects of a 20min preincubation with the antioxidant
mixture SOD (300U/mL) + catalase (250U/mL) on the 8-Br-
cGMP-induced VASP phosphorylation at Ser 239 in the presence
of 5 and 25mmol/L glucose. Blots are representative of six different
experiments. SOD and catalase did not modify the significant
increase of VASP phosphorylation induced by 8-Br-cGMP in the
presence of 5mmol/L glucose but significantly increased the extent
of 8-Br-cGMP-induced VASP phosphorylation in the presence of
glucose 25mmol/L (𝑃 < 0.0001).
3.5. The High Glucose-Induced Increase of ROS Production
Is Prevented by PKC and NADPH Oxidase Inhibitors. As
shown in Figure 6, a 180min incubation with 25mmol/L
glucose increased ROS production, measured by the DCF-
DA assay specific for H
2
O
2
(𝑛 = 6, 𝑃 < 0.0001).
This increase was inhibited by preincubation with the PKC
inhibitor chelerythrine (2.5𝜇mol/L) (𝑛 = 6, 𝑃 < 0.0001),
the NADPH-oxidase inhibitor apocynin (10 𝜇mol/L) (𝑛 =
6, 𝑃 < 0.0001), and, as expected, by SOD (300U/mL) +
catalase (250U/mL) (𝑛 = 6, 𝑃 < 0.0001). With the three
inhibitors, ROS values were similar to those measured in the
presence of 5mmol/L glucose (𝑃 = ns). ROS production
was unaffected by incubation with 10 𝜇mol/L rotenone and
50 𝜇mol/L allopurinol (𝑃 = ns versus 25mmol/L glucose for
both).
Similar results have been obtained by the lucigenin assay,
specific for O
2
−. In particular, when values are expressed
as percent of baseline values at 5mmol/L glucose, in the
presence of 180min incubation with 25mmol/L glucose the
O
2
− production was 144.7 ± 22.5% (𝑛 = 6, 𝑃 < 0.0001):
this increase was completely inhibited by preincubation with
the PKC inhibitor chelerythrine (2.5 𝜇mol/L) (𝑛 = 6, 𝑃 <
0.0001), theNADPH-oxidase inhibitor apocynin (10 𝜇mol/L)
(𝑛 = 6, 𝑃 < 0.0001), and, as expected, by SOD (300U/mL)
(𝑛 = 6, 𝑃 < 0.0001). With the three inhibitors, O
2
− values
were similar to those measured in the presence of 5mmol/L
glucose (𝑃 = ns).
3.6. High Glucose Increases PKC Alpha/Beta Phosphoryla-
tion. As shown in Figure 7, 25mmol/L glucose induces a
PKC 𝛼/𝛽II activating phosphorylation without modifying
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Figure 6: Effects of a 180min incubation with 5 and 25mmol/L
glucose on ROS concentrations in the absence or in the pres-
ence of a 20min preincubation with the PKC inhibitor chel-
erythrine (2.5𝜇mol/L), the NADPH-oxidase inhibitor apocynin
(10𝜇mol/L), the mitochondrial electron transport chain complex
inhibitor rotenone (10 𝜇mol/L), the xanthine oxidase inhibitor
allopurinol (50𝜇mol/L), and a mixture of SOD and catalase
(300U/mL/250U/mL) (𝑛 = 6). ROS values in the presence of
25mmol/L glucose were significantly higher than in the presence
of 5mmol/L glucose (𝑛 = 6, 𝑃 < 0.0001). SOD + catalase, chel-
erythrine, and apocynin blunted the effects of glucose 25mmol/L
(𝑃 < 0.0001 for each), whereas rotenone and allopurinol did not
modify the high glucose effects (𝑃 = ns).
protein expression. In particular, a 180min incubation with
25mmol/L glucose in comparison to 5mmol/L glucose (i)
did not modify the expression of total PKC 𝛼/𝛽/𝛾 (𝑛 = 4,
𝑃 = ns); (ii) increased the phosphorylation of PKC 𝛼/𝛽II at
Thr 638/641 (𝑛 = 4, 𝑃 < 0.0001).
3.7. In the Presence of High Glucose, the cGMP-Induced VASP
Phosphorylation Is Increased by PKC and NADPH Oxidase
Inhibitors. As shown in Figure 8, the VASP phosphorylation
induced by 8-Br-cGMP in the presence of 25mmol/L glucose
was significantly enhanced by both 2.5𝜇mol/L chelerythrine
and 10 𝜇mol/L apocynin (𝑛 = 4,𝑃 < 0.0001 for both) and was
unaffected by 10 𝜇mol/L rotenone.
4. Discussion
This study shows that, in cultured rat aortic VSMC, a short-
term incubation with high glucose impairs the NO-induced
VASP phosphorylation at serine 239 and that this effect is
not due to a reduced cGMP synthesis but due to a reduced
cGMP action and involves oxidative stress. The proposed
mechanism is the following sequence of events: (i) high
glucose activates PKC; (ii) PKC activates NADPH oxidase;
(iii) NADPH oxidase increases the production of superoxide
anion, and, consequently, of hydrogen peroxide; (iv) ROS
impair the cGMP ability to phosphorylate VASP at serine 239.
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Figure 7: Effects of a 180min incubation with 5 and 25mmol/L
glucose on nonphosphorylated PKC 𝛼/𝛽/𝛾 isoforms and on PKC
𝛼/𝛽II phosphorylated at Thr 638/641. Blots are representative of
four different experiments. Glucose 25mmol/L did not modify
the expression of nonphosphorylated PKC 𝛼/𝛽/𝛾 isoforms and
increased PKC 𝛼/𝛽II phosphorylation (𝑃 < 0.0001).
As far as we know, this study provides the first evidence
of the high glucose ability to reduce the NO/cGMP-induced
VASP phosphorylation in cultured VSMC: a previous study,
carried out with a long-term incubation with high glucose,
demonstrated a similar inhibition in cultured human lung
microvascular endothelial cells [32]. A reduced VASP phos-
phorylation was also observed in endothelial progenitor cells
derived from two diabetic patients and therefore exposed to
high glucose “in vivo” [32].
Our study also shows that oxidative stress plays a piv-
otal role in the high glucose-induced impairment of the
NO/cGMP signalling in VSMC, since this impairment is
completely prevented by the antioxidant mixture SOD +
catalase.
As it is well known, during the physiological cellular
metabolism oxygen undergoes a cascade of reductions,
leading to the sequential production of superoxide anion,
which is dismutated by superoxide dismutases (SOD) to
hydrogen peroxide, which is catalyzed to H
2
O by catalase;
superoxide anion and hydrogen peroxide belong to the class
of the “Reactive Oxygen Species” (ROS); excessive increases
of ROS lead to the so-called “oxidative stress,” a common
phenomenon in many vascular diseases, such as diabetes
mellitus, arterial hypertension, hypercholesterolemia, and
heart failure, as reviewed [33–35].
In our study, SOD and catalase completely prevented the
inhibiting influence exerted by high glucose on the VASP
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Figure 8: Effects of a 20min preincubation with the PKC inhibitor
chelerythrine (2.5𝜇mol/L), theNADPH-oxidase inhibitor apocynin
(10𝜇mol/L), and the mitochondrial electron transport chain com-
plex inhibitor rotenone (10𝜇mol/L), on the 8-Br-cGMP-induced
VASP phosphorylation at Ser 239 in the presence of 25mmol/L
glucose. Blots are representative of four different experiments.
Chelerythrine and apocynin significantly increased the extent of 8-
Br-cGMP-inducedVASPphosphorylation in the presence of glucose
25mmol/L (𝑃 < 0.0001 for both), which was not modified by
rotenone (𝑃 = ns).
phosphorylation induced by the NO/cGMP signalling,
underlining the role of oxidative stress in this phenomenon.
Our working hypothesis was that high glucose increases
in a short-term oxidative stress by a PKC-induced activation
of NADPH oxidase; this hypothesis has been confirmed by
the experiments carried out by measuring ROS concentra-
tions, in which both PKC and NADPH oxidase inhibition
impaired the stimulating effect of high glucose, whereas
inhibitors of other potential ROS sources, such as mito-
chondrial respiratory chain complex and xanthine oxidase,
did not modify the high glucose effects. Interestingly, PKC
and NADPH oxidase inhibitors were also able to restore
the extent of the cGMP-induced VASP phosphorylation
impaired by high glucose. As it is well known, NADPH
oxidase is the major source of ROS in VSMC [36]. We
recently demonstrated that also oleic acid increases oxidative
stress in VSMC by a mechanism involving both PKC and
NADPH oxidase [37]. Previous observations carried out in
our laboratory demonstrated that a 24 h incubation of rat
VSMC with hydrogen peroxide reduces the cGMP-induced
VASP phosphorylation, indicating a peculiar role of oxidative
stress in the impairment of cGMP signalling [31].
In rat aortic VSMC, it has been demonstrated that a long-
term (24–48 h) incubation with high glucose in the absence
of exposure to NO donors or cGMP reduces the constitu-
tive PKG-1 synthesis and, consequently, the PKG-induced
VASP phosphorylation; also in this case the phenomenon is
prevented by NADPH oxidase and PKC inhibitors [38]. The
same authors demonstrated that a 3 h incubation with high
glucose failed to modify PKG-1 expression [38]; thus, the
results we obtained in the present study cannot be attributed
to a reduced synthesis of PKG.
Independently of high glucose, a ROS-mediated reduc-
tion of PKG activity without any change in PKG expression
has been observed in cultured VSMC from ovine fetal
intrapulmonary veins exposed for 30min to hypoxia and
attributed to posttranslational, ROS-induced PKG nitration
in tyrosine residues [39]; interestingly, the ROS-mediated
downregulation of PKG activity wasmore evident in the pres-
ence of cGMP, suggesting that one or more residues within
the cGMP-binding region of PKG are susceptible to ROS-
induced posttranslational modifications [39]. In agreement
with this observation, in our experimental conditions the
extent of VASP phosphorylation—a reliable marker of PKG
activity in vascular tissue [19]—was reduced by high glucose
via oxidative stress only in the presence of NO or cGMP.
In conclusion, our study originally demonstrates the abil-
ity of high glucose to influence the NO/cGMP/PKG/VASP
pathway in isolated, cultured VSMC by a mechanism involv-
ing the increase of oxidative stress mediated by a PKC-
induced enhancement of the NADPH oxidase activity. It
therefore provides some new information to further explain
the interesting results of previous investigations carried out
in aortas from rats sacrificed weeks after a streptozotocin
injection, representing a classical animal model of “in vivo”
hyperglycaemia [40, 41]. Obviously, when hyperglycaemia
occurs “in vivo,” high glucose affects many different tissues
with the occurrence of the well-known intercellular interplay
mediated by the release of differentmolecules, a phenomenon
prevented by the “in vitro” incubation with high glucose
of isolated cells. In any case, in these “in vivo” studies it
has been demonstrated that streptozotocin-induced diabetes
causes an impairment of endothelium-dependent [40, 41] and
endothelium-independent vasodilation [41] and increases
NADPH oxidase activity and expression and superoxide
production in aorta [40, 41], the last phenomenon being pre-
vented by the incubation of aortic rings with PKC inhibitors
and by their “in vivo” administration [40]. Interestingly, “in
vivo” administration of a PKC inhibitor markedly decreased
superoxide anion production both in the endothelial and in
the media layers of the aorta, indicating the occurrence of a
PKC-mediated increase of oxidative stress inVSMC, themain
component of the media [40].
Furthermore, acetylcholine induced an increase of VASP
phosphorylation at serine 239 in aortic tissue of control rats,
but not in that of rats with streptozotocin-induced diabetes;
owing to the experimental design, this phenomenon has
been attributed to the marked reduction of the acetylcholine-
induced NO production in the vascular endothelium [41].
Our study, carried out in isolated cultured VSMC, adds a
further piece of information on the mechanisms of glucose-
induced impairment of VASP phosphorylation in vascular
tissues, since it clarifies that in VSMC this impairment is due
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to a defect of the cGMP signalling and therefore occurs also
independently of the reduced NO synthesis and bioavailabil-
ity caused by the glucose effects on vascular endothelium.
Finally, our present study provides the first demonstra-
tion of the ability of high glucose to rapidly reduce the
NO/cGMP signalling in VSMC; this fact could be relevant
to explain one of the possible mechanisms by which the so-
called “glucose spikes” occurring “in vivo” in diabetic patients
negatively influence vascular function [26].
5. Conclusions
In conclusion, in cultured aortic VSMC a short-term incu-
bation with high glucose reduces the ability of both NO
and cGMP to phosphorylate VASP at Ser 239 with a mech-
anism mediated by oxidative stress. As described in the
Introduction, VASP phosphorylation is deeply involved in
many antihypertensive and antiatherogenic biological actions
exerted by the NO/cGMP/PKG pathway, such as modulation
of cell adhesion, motility, migration, and contraction. Since
the impairment of the NO pathway plays a pivotal role in the
pathogenesis of the atherothrombotic vascular complications
of diabetes, our results, by identifying a potential mechanism
involved in the reduced NO action in VSMC, could have
a clinical relevance. In particular, the results of our study
can clarify another mechanism of the harmful vascular
consequences of the so-called “glucose spikes” occurring “in
vivo” in diabetic patients, which have been attributed to
acute increases of oxidative stress, indicating an involvement
of VSMC beyond the previously described involvement of
vascular endothelium.
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